Sylwia Łapińska-Szumczyk

Sylwia Łapińska-Szumczyk

Auto-generated profile, based on publicly available information

Sylwia Łapińska-Szumczyk

Department of Gynecology, Gyneacological Oncology and Gynecological Endocrinology, Medical University of Gdańsk, 80-211 Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MŁMarta Łukasiewicz
Marta Łukasiewicz
KPKrzysztof Pastuszak
Krzysztof Pastuszak
SŁSylwia Łapińska-Szumczyk
Sylwia Łapińska-Szumczyk
RRRobert Różański
Robert Różański
SVSjors G.J.G. In 't Veld
Sjors G.J.G. In 't Veld
JJJacek Jassem
Jacek Jassem
Background: Liquid biopsy is a minimally invasive collection of a patient body fluid sample. In oncology, they offer several advantages compared to traditional tissue biopsies. However, the potential of this method in endometrial cancer (EC) remains poorly explored. We studied the utility of tumor educated platelets (TEPs) and circulating tumor DNA (ctDNA) for preoperative EC diagnosis, including histology determination. Methods: TEPs from 295 subjects (53 EC patients, 38 patients with benign gynecologic conditions, and 204 healthy women) were RNA-sequenced. DNA sequencing data were obtained for 519 primary tumor tissues and 16 plasma samples. Artificial intelligence was applied to sample classification. Results: Platelet-dedicated classifier yielded AUC of 97.5% in the test set when discriminating between healthy subjects and cancer patients. However, the discrimination between endometrial cancer and benign gynecologic conditions was more challenging, with AUC of 84.1%. ctDNA-dedicated classifier discriminated primary tumor tissue samples with AUC of 96% and ctDNA blood samples with AUC of 69.8%. Conclusions: Liquid biopsies show potential in EC diagnosis. Both TEPs and ctDNA profiles coupled with artificial intelligence constitute a source of useful information. Further work involving more cases is warranted.

Verified
Journal Article
Open access
PDF file
Maria Anna SmolleMaria Anna Smolle
Maria Anna Smolle
PCPiotr Czapiewski
Piotr Czapiewski
SLSylwia Lapińska-Szumczyk
Sylwia Lapińska-Szumczyk
HMHanna Majewska
Hanna Majewska
ASAnna Supernat
Anna Supernat
JHJohannes Haybäck
Johannes Haybäck
Whilst the role of eukaryotic translation initiation factors (eIFs) has already been investigated in several human cancers, their role in endometrial cancer (EC) is relatively unknown. In the present retrospective study, 279 patients with EC (1180 samples) were included (mean age: 63.0 years, mean follow-up: 6.1 years). Samples were analysed for expression of 7 eIFs subunits (eIF2α, eIF3c, eIF3h, eIF4e, eIF4g, eIF5, eIF6) through immunohistochemistry and western blotting. Fifteen samples of healthy endometrium served as controls. Density and intensity were assessed and mean combined scores (CS) calculated for each patient. Upon immunohistochemistry, median eIF5 CS were significantly higher in EC as compared with non-neoplastic tissue (NNT, p < 0.001), whilst median eIF6 CS were significantly lower in EC (p < 0.001). Moreover, eIF5 (p = 0.002), eIF6 (p = 0.032) and eIF4g CS (p = 0.014) were significantly different when comparing NNT with EC grading types. Median eIF4g CS was higher in type II EC (p = 0.034). Upon western blot analysis, eIF4g (p < 0.001), peIF2α (p < 0.001) and eIF3h (p < 0.05) were significantly overexpressed in EC, while expression of eIF3c was significantly reduced in EC as compared with NNT (p < 0.001). The remaining eIFs were non-significant. Besides tumour stage (p < 0.001) and patient’s age (p < 0.001), high eIF4g CS-levels were independently associated with poor prognosis (HR: 1.604, 95%CI: 1.037–2.483, p = 0.034). The other eIFs had no prognostic significance. Notably, the independent prognostic significance of eIF4g was lost when adding tumour type. Considering the difficulties in differentiating EC type I and II, eIF4g may serve as a novel prognostic marker indicating patient outcome.

1 January 2016 in Ginekologia Polska
Verified
Journal Article
Open access
SŁSylwia Łapińska-Szumczyk
Sylwia Łapińska-Szumczyk
ASAnna Supernat
Anna Supernat
AZAnna Zaczek
Anna Zaczek
HMHanna Majewska
Hanna Majewska
JGJacek Gulczynski
Jacek Gulczynski
DWDariusz Wydra
Dariusz Wydra

1 January 2014
Verified
Journal Article
Closed access
SLSylwia Lapinska-Szumczyk
Sylwia Lapinska-Szumczyk
ASAnna Supernat
Anna Supernat
AZAnna J. Zaczek
Anna J. Zaczek
HMHanna Majewska
Hanna Majewska
JGJacek Gulczynski
Jacek Gulczynski
DWDariusz Wydra
Dariusz Wydra